Insights from 100 years of research with probiotic E. coli
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
A century ago, Alfred Nissle discovered that intentional intake of particular strains of Escherichia coli could treat patients suffering from infectious diseases. Since then, one of these strains became the most frequently used probiotic E. coli in research and was applied to a variety of human conditions. Here, properties of that E. coli Nissle 1917 strain are compared with other commercially available E. coli probiotic strains, with emphasis on their human applications. A literature search formed the basis of a summary of research findings reported for the probiotics Mutaflor, Symbioflor 2, and Colinfant. The closest relatives of the strains in these products are presented, and their genetic content, including the presence of virulence, genes is discussed. A similarity to pathogenic strains causing urinary tract infections is noticeable. Historic trends in research of probiotics treatment for particular human conditions are identified. The future of probiotic E. coli may lay in what Alfred Nissle originally discovered: to treat gastrointestinal infections, which nowadays are often caused by antibiotic-resistant pathogens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Revised Estimates for the Number of Human and Bacteria Cells in the Body
Sender, R., Fuchs, S., & Milo, R. (2016) · PLOS Biology · doi:10.1371/journal.pbio.1002533 · Cited by 5,425
Kruis, W., Frič, P., Pokrotnieks, J., Lukáš, M., Fixa, B., Kaščák, M., Kamm, M. A., Weismueller, J., Beglinger, C., Stolte, M., et al. (2004) · Gut · doi:10.1136/gut.2003.037747 · Cited by 1,285 · cited 1×
“These results were confi rmed 2 years later by another research group [30] and again in a larger study by the research group of the 1997 study [31].”
ResultFord, A. C., Quigley, E. M. M., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E. E., Spiegel, B. M. R., & Moayyedi, P. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.202 · Cited by 747 · cited 1×
“coli, comparing the Symbiofl or 2 study mentioned above [22] with an EcN study [24]; in the meta-analysis, the effects were positive and comparable [25].”
ResultProbiotic Bacteria Reduce Salmonella Typhimurium Intestinal Colonization by Competing for Iron
Deriu, E., Liu, J. Z., Pezeshki, M., Edwards, R. A., Ochoa, R. J., Contreras, H., Libby, S. J., Fang, F. C., & Raffatellu, M. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.06.007 · Cited by 550 · cited 1×
“The antagonistic effects of EcN are not only due to bacteriocins: a highly effi cient uptake of iron helps EcN outcompeting pathogenic Salmonella Typhimurium, at least in the murine gut [99].”
BackgroundPatzer, S. I., Baquero, M. R., Bravo, D., Moreno, F., & Hantke, K. (2003) · Microbiology · doi:10.1099/mic.0.26396-0 · Cited by 233
Zhang, Y., Zhang, Y., Xia, L., Zhang, X., Ding, X., Yan, F., & Wu, F. (2012) · Applied and Environmental Microbiology · doi:10.1128/aem.01390-12 · Cited by 138 · cited 1×
“, azurin) can enhance the effectivity of bacterial cancer treatment [103], while ferritin-overexpression provides a practical marker for tumor detection by magnetic resonance imaging (MRI) [104].”
BackgroundVassiliadis, G., Destoumieux-Garzón, D., Lombard, C., Rebuffat, S., & Peduzzi, J. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00744-09 · Cited by 128 · cited 1×
“The phenotype he determined was most probably the result of microcins; it is now known that EcN produces microcins MccM and MccH47 [72].”
BackgroundEnck, P., Zimmermann, K., Menke, G., & Klosterhalfen, S. (2009) · Zeitschrift für Gastroenterologie · doi:10.1055/s-2008-1027702 · Cited by 100 · cited 2×
“coli, comparing the Symbiofl or 2 study mentioned above [22] with an EcN study [24]; in the meta-analysis, the effects were positive and comparable [25].”
MethodResultEscherichia coli Nissle 1917 (Mutaflor): New Insights into an Old Probiotic Bacterium
Jacobi, C. A., & Malfertheiner, P. (2011) · Digestive Diseases · doi:10.1159/000333307 · Cited by 95 · cited 2×
“Some citations state that the lucky soldier remained free from “diarrhea” [58] or “shigellosis” [59] while yet others mention his resistance was against typhoid fever.”
BackgroundZschüttig, A., Auerbach, C., Meltke, S., Eichhorn, C., Brandt, M., Blom, J., Goesmann, A., Jarek, M., Scharfe, M., Zimmermann, K., et al. (2015) · Genome Announcements · doi:10.1128/genomea.01330-14 · Cited by 16
Self-citation
Cited by
The microbiome and human cancer
Sepich-Poore, G. D., Zitvogel, L., Straussman, R., Hasty, J., Wargo, J. A., & Knight, R. (2021) · Science · doi:10.1126/science.abc4552 · Cited by 1,332
Gut Microbiome: Profound Implications for Diet and Disease
Hills, R., Pontefract, B., Mishcon, H., Black, C., Sutton, S., & Theberge, C. (2019) · Nutrients · doi:10.3390/nu11071613 · Cited by 1,092
The Human Gut Microbiome: From Association to Modulation
Schmidt, T. S. B., Raes, J., & Bork, P. (2018) · Cell · doi:10.1016/j.cell.2018.02.044 · Cited by 845
Probiotics Mechanism of Action on Immune Cells and Beneficial Effects on Human Health
Mazziotta, C., Tognon, M., Martini, F., Torreggiani, E., & Rotondo, J. C. (2023) · Cells · doi:10.3390/cells12010184 · Cited by 889
Sorbara, M. T., & Pamer, E. G. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00667-9 · Cited by 468
Metadata
- Authors
- Wassenaar, T. M.
- Venue
- European Journal of Microbiology and Immunology
- Publisher
- Akademiai Kiado Zrt.
- Published
- 2016-09
- Volume
- 6
- Issue
- 3
- Pages
- 147-161
- ISSN
- 2062-509X (ISSN-L)
- OpenAlex
- W2526691844
- Cited by
- 145
- References
- 12
- FWCI
- 17.63
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Insights from 100 years of research with probiotic E. coli. https://app.cochat.ai/papers/10.1556/1886.2016.00029
- The paper
- Wassenaar, T. M. (2016). Insights from 100 years of research with probiotic E. coli. European Journal of Microbiology and Immunology. https://doi.org/10.1556/1886.2016.00029
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.